The Royal College of Pathologists (RCPA) and then RCPA Quality Assurance Programs Pty Ltd (RCPAQAP), a company independent from but aligned with the RCPA, have been producing proficiency testing programs (PTP) for infectious diseases for 52 years. This involves sending infectious disease material in surveys to over 80 countries worldwide throughout any year. The PTP panels are developed depending on the prevalence of diseases, which requires flexible panel composition and dynamic enrolments. The Defence Trade Controls Act was introduced in 2012 as part of a wider international regulatory counter-proliferation framework. In 2017, the inclusion of inactivated infectious diseases as controlled microorganisms in the Defence Strategic Goods List (DSGL) had the potential to completely disrupt the RCPAQAP business model in the provision of infectious disease PTP. Some strategies for mitigating this risk are discussed in this paper.

皇家病理学家学院（RCPA）和RCPA质量保证计划有限公司（RCPAQAP）是一家独立于RCPA但与RCPA保持一致的公司，已经为传染病制定了能力验证计划（PTP）52年。这涉及每年通过调查向全球80多个国家/地区发送传染病资料。根据疾病的流行程度开发PTP面板，这需要灵活的面板组成和动态注册。国防贸易控制法于2012年推出，是更广泛的国际反扩散监管框架的一部分。在2017年，将灭活的传染病作为受控微生物列入《国防战略物资清单》（DSGL）有可能完全破坏提供传染病PTP时的RCPAQAP商业模式。本文讨论了一些缓解此风险的策略。